Pharminent

Kite inks China, Japan deals ahead of possible CAR-T drug approval

Through a joint venture with China’s Fosun Pharma, the CAR-T specialist gains a foothold for its lead drug candidate in the world’s second biggest pharmaceutical market. http://www.biopharmadive.com/news/Kite-Fosun-Car-T-China/433737/

Filed under: Cancer, Immunotherapy